Patents matching “treatment”

US 11071781

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Provectus Pharmatech, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

US 11072792

Materials and methods for treatment of usher syndrome type 2A

CRISPR THERAPEUTICS AG · Granted Jul 27, 2021 · Expires Jul 22, 2041

US 11072600

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

The Regents of the University of California · Granted Jul 27, 2021 · Expires Jul 22, 2041

US 11065347

Methods for the treatment of Danon disease and other disorders of autophagy

The Regents of the University of California · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11065262

Topical treatment of wounds with statins and cholesterol for scar reduction

Northwestern University · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11066417

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

Vertex Pharmaceuticals Incorporated · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11066405

Bicyclic compounds and their use in the treatment of cancer

TEMPEST THERAPEUTICS, INC. · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11059796

Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 13, 2021 · Expires Jul 8, 2041

US 11060110

Adeno-associated virus vectors for treatment of glycogen storage disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 13, 2021 · Expires Jul 8, 2041

US 11059906

Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma

Takeda Pharmaceutical Company Limited · Granted Jul 13, 2021 · Expires Jul 8, 2041

US 11053310

Antibodies for the treatment of cancers

The Regents of the University of California · Granted Jul 6, 2021 · Expires Jul 1, 2041

US 11052064

Compositions, methods and systems for the treatment of cutaneous disorders

Verrica Pharmaceuticals Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

US 11045504

Compositions and methods for treatment of cancer using bacteria

Decoy Biosystems, Inc. · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11045472

Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Arcus Biosciences, Inc. · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11046785

Compositions and methods for treatment of diabetic macular edema

Takeda Pharmaceutical Company Limited · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11045482

Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Corcept Therapeutics Incorporated · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11040039

Treatment of inflammatory disorders

Aldeyra Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

US 11040115

Method for the treatment of lysosomal storage diseases

Sangamo Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

US 11034739

Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases

The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11033569

Compounds,Compositions, and methods for the treatment of disease

Sperovie Biosciences, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11034667

Selective histone deacetylase inhibitors for the treatment of human disease

Shuttle Pharmaceuticals, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11033537

LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

Biomed Valley Discoveries, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11033554

Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

United States Government as represented by the Department of Veterans Affairs · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11026997

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

REGENERON PHARMACEUTICALS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041